Raymond James Rates Ventas (VTR) buy, $94 Price Target

Raymond James analyst David Rodgers boosts Ventas, Inc. with a buy rating and a $94 target, a 10.11% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 11:01 AM EDT · Updated Jun 24, 2026, 5:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Raymond James rated Ventas, Inc. ($VTR) "buy" with a $94 price target on June 17, 2026.

Since the rating, $VTR is up 5.4% after 1 week, up 17.7% after 1 month and up 5.8% to date (from the $81.18 close on Jun 17, 2026).

VTR Ventas, Inc.

$85.86 +13.08% year to date

Daily close · Oct 16, 2026

Key Points

Raymond James analyst David Rodgers reinstated Ventas, Inc. with a buy rating and a $94 price target.
Raymond James's $94 price target implies 10.11% upside from Ventas, Inc.'s ($VTR) current $85.37 share price.
Shares of Ventas, Inc. traded near $83.89 with a market cap of $40.78 billion and a P/E ratio of 152.5.
Several insiders, including Michael Embler, have been actively buying Ventas stock, indicating confidence.

Get $VTR trade alerts by text

We text you when insiders, Congress or big funds trade $VTR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ventas, Inc. alert may contain errors. Disclosures

Raymond James has upgraded its rating on Ventas, Inc. (NYSE: VTR) to a buy, setting a price target of $94. This move by analyst David Rodgers on June 17, 2026, suggests a positive outlook for the company.

Analysts Set New Price Targets

On June 17, 2026, Raymond James reinstated Ventas, Inc. with a buy rating and a $94 price target. This follows a series of maintained buy ratings from other firms, such as Wells Fargo with a $96 target on June 1, 2026, and Jefferies with a $100 target on May 13, 2026. The consensus among analysts is a buy, with an average target price of $96.8 based on 20 opinions.

Other Institutional Activity in Ventas, Inc.

BlackRock, Inc. grew its holdings by 1,489,789 shares, ending with 56,582,774 shares worth about $4.63 billion. Vanguard Portfolio Management LLC added 41,261,965 shares, now holding shares valued at approximately $3.37 billion. Meanwhile, JPMorgan Chase & Co. increased its stake by 7,252,685 shares to a total of 35,379,149 shares, valued around $2.89 billion.

Ventas, Inc. Stock Down 1.5%

Shares of NYSE:VTR traded near $83.89. Ventas, Inc. has a market cap of $40.78 billion and a P/E ratio of 152.5, with a forward P/E of 99.1. The stock has a 52-week low of $61.76 and a high of $91.06. It has a 50-day moving average of $85.26 and a 200-day moving average of $79.18. The company's beta is 0.734, indicating lower volatility compared to the market.

12-month forecast

$VTR price target

Ventas, Inc. daily closes and this analyst's $94 target. Not advice.

Recent Earnings

Ventas, Inc. reported revenue of $6.11 billion, with a growth rate of 21.9%. The company has a net margin of 4.26% and a return on equity of 2.14%. The next earnings report is expected on July 29, 2026.

Dividend

The company pays an annual dividend rate of $2.00, yielding 2.38%, with a payout ratio of 356.36%. This provides a steady income stream for investors.

Insider Buying and Selling at Ventas, Inc.

Several insiders have been active in Ventas stock. On June 3, 2026, Michael Embler bought 2,500 shares at an average price of $78.81. Earlier in May, Melody Barnes, Matthew Lustig, and Sumit Roy each purchased 2,047 shares at $90.35. These transactions were not part of a planned trading program.

About Ventas, Inc.

Ventas, Inc. is a leading real estate investment trust (REIT) based in Chicago, Illinois. It focuses on healthcare facilities, including senior housing communities, outpatient medical buildings, and research centers. The company, led by CEO Debra A. Cafaro, manages approximately 1,400 properties across North America and the UK, catering to the growing aging population. Ventas employs 542 people and leverages its operational expertise and data-driven insights to enhance its portfolio.

Bottom Line

Raymond James's upgrade to a buy rating for Ventas, Inc. highlights a positive sentiment in the market. The company's diverse healthcare-focused real estate portfolio and strong institutional interest make it a stock to watch. Remember, analyst ratings and 13F filings are backward-looking and may not reflect the current market conditions.